Chronic myeloid leukemia (CML) was a well-known myeloproliferative neoplasm and a disease of haemopoietic stem cells due to BCR-ABL fusion protein arising from a translocation t(9;22), known as the Philadelphia chromosome. Imatinib (Gleevec), a selective small molecule inhibitor of Bcr-Abl kinase, has been confirmed as the standard drug therapy for CML. Discovery of imatinib led to the availability of a molecular-targeted therapy as a new model of cancer treatment and challenged the molecular target cancer treatment trend from non-targeted cytotoxic chemotherapy. We reviewed the advancement of chronic myeloid leukemia treatment in the area of imatinib.

서 론
 본 론
  Imatinib Mesilate(Gleevec)의 개발
  Imatinib 저항성의 대책 및 치료 실패 환자에서의 2세대 TKI
  Imatinib의 용량 증량
  Dasatinib (Sprycel ®)
  Nilotinib(Tasigna ®)
 요 약
 참고문헌

• 박상곤(조선대학교병원 종양혈액내과) | Sang Gon Park Corresponding author